Xia Jufeng, Inagaki Yoshinori, Song Peipei, Sawakami Tatsuo, Kokudo Norihiro, Hasegawa Kiyoshi, Sakamoto Yoshihiro, Tang Wei
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo.
Biosci Trends. 2016 Nov 15;10(5):327-336. doi: 10.5582/bst.2016.01110. Epub 2016 Jun 25.
Traditional Chinese medicine (TCM), as a type of complementary and alternative medicine (CAM), is a sophisticated and time-honored form of healthcare in China. Many TCMs are widely used to treat hepatitis B and hepatitis C in countries like China, Japan, and South Korea. Since conventional clinical preparations like interferon-α cause obvious dose-dependent adverse reactions and drug resistance, TCMs and related bioactive compounds have garnered increasing attention from physicians and medical researchers. Thus far, a number of TCMs and compounds have been used to inhibit the hepatitis B virus (HBV) or hepatitis C virus (HCV) in vitro, in vivo, and even in clinical trials. The current review summarizes TCMs and related compounds that have been used to inhibit HBV or HCV. Most of these medicines are derived from herbs. HepG2.2.15 cells have been used to study HBV in vitro and Huh7.5 cells have been similarly used to study HCV. Ducks have been used to study the anti-HBV effect of new medication in vivo, but there are few animal models for anti-HCV research at the present time. Thus far, a number of preclinical studies have been conducted but few clinical trials have been conducted. In addition, a few chemically modified compounds have displayed greater efficacy than natural products. However, advances in TCM research are hampered by mechanisms of action of many bioactive compounds that have yet to be identified. In short, TCMs and related active compounds are a CAM that could be used to treat HBV and HCV infections.
传统中医（TCM）作为一种补充和替代医学（CAM），在中国是一种成熟且历史悠久的医疗保健形式。在中国、日本和韩国等国家，许多中药被广泛用于治疗乙型肝炎和丙型肝炎。由于传统临床制剂如α干扰素会引起明显的剂量依赖性不良反应和耐药性，中药及其相关生物活性化合物越来越受到医生和医学研究人员的关注。到目前为止，许多中药及其化合物已在体外、体内甚至临床试验中用于抑制乙型肝炎病毒（HBV）或丙型肝炎病毒（HCV）。本综述总结了已用于抑制HBV或HCV的中药及其相关化合物。这些药物大多源自草药。HepG2.2.15细胞已用于体外研究HBV，Huh7.5细胞也同样用于研究HCV。鸭子已用于体内研究新药的抗HBV作用，但目前抗HCV研究的动物模型很少。到目前为止，已经进行了一些临床前研究，但临床试验很少。此外，一些化学修饰的化合物显示出比天然产物更高的疗效。然而，许多生物活性化合物的作用机制尚未确定，这阻碍了中医研究的进展。简而言之，中药及其相关活性化合物是一种可用于治疗HBV和HCV感染的补充和替代医学。
